Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.

about

Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.

Item

http://www.wikidata.org/entity/Q49553324

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Practical Management of Toxici ...... tive Chronic Myeloid Leukemia.

@en

Practical Management of Toxici ...... tive Chronic Myeloid Leukemia.

@nl

type

Item

label

Practical Management of Toxici ...... tive Chronic Myeloid Leukemia.

@en

Practical Management of Toxici ...... tive Chronic Myeloid Leukemia.

@nl

prefLabel

Practical Management of Toxici ...... tive Chronic Myeloid Leukemia.

@en

Practical Management of Toxici ...... tive Chronic Myeloid Leukemia.

@nl

P1476

Practical Management of Toxici ...... tive Chronic Myeloid Leukemia.

@en

P2093

C Gambacorti-Passerini

http://www.w3.org/2001/XMLSchema#string

H J Khoury

http://www.w3.org/2001/XMLSchema#string

T H Brümmendorf

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.

P304

578-587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1093/ANNONC/MDY019

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29385394

http://www.w3.org/2001/XMLSchema#string

P921

amine

nitrile

chronic myeloid leukemia

P932

5888919

http://www.w3.org/2001/XMLSchema#string